# Johnson & Johnson

> Johnson & Johnson is a 139-year-old American healthcare company headquartered in New Brunswick, New Jersey, and the only firm of its scale to run two businesses at once: Innovative Medicine (prescription drugs in oncology, immunology, neuroscience, cardiovascular and pulmonary hypertension) and MedTech (surgical, cardiovascular, orthopedic and vision devices). After spinning off its consumer brands as Kenvue in 2023, J&J now operates as a pure-play prescription-and-device maker, reporting $94.2 billion in 2025 sales with roughly 142,000 employees worldwide.

- **Founded:** 1886
- **Headquarters:** New Brunswick, New Jersey, United States
- **Founders:** Robert Wood Johnson (Co-founder & first President), James Wood Johnson (Co-founder), Edward Mead Johnson (Co-founder)
- **Team size:** ~142,000 employees
- **Products:** Innovative Medicine (Pharmaceuticals), MedTech (Medical Devices), Ottava surgical robotics system, Carvykti, Darzalex
- **Notable:** Grew 2025 sales to $94.2 billion, up about 6% year over year, Operates 11 'priority platforms' that each generate more than $1 billion in annual sales, Darzalex surpassed $3 billion in quarterly sales in 2025

## Products & services

- **Innovative Medicine (Pharmaceuticals)** — Prescription medicines across oncology, immunology, neuroscience, cardiovascular and pulmonary hypertension. Flagship products include Darzalex (multiple myeloma), Stelara and Tremfya (immunology), and Carvykti (CAR-T cell therapy). Segment reported about $60.4 billion in 2025 sales.
- **MedTech (Medical Devices)** — Surgery, cardiovascular, orthopedics and vision devices, including electrophysiology catheters, the Shockwave intravascular lithotripsy platform and Abiomed's Impella heart pumps. Segment reported about $33.8 billion in 2025 sales.
- **Ottava surgical robotics system** — A soft-tissue robotic surgery platform in development; FDA submission is a key 2026 execution target.
- **Carvykti** — CAR-T cell therapy for multiple myeloma developed with Legend Biotech.
- **Darzalex** — Antibody therapy for multiple myeloma that surpassed $3 billion in quarterly sales during 2025.

## Achievements

- Grew 2025 sales to $94.2 billion, up about 6% year over year
- Operates 11 'priority platforms' that each generate more than $1 billion in annual sales
- Darzalex surpassed $3 billion in quarterly sales in 2025
- Completed the Kenvue consumer-health separation in 2023, generating about $13.2 billion
- Maintained one of the longest streaks of consecutive annual dividend increases in the market (60+ years)
- One of a small number of companies to have held a top-tier AAA credit rating

## Latest updates

- **2026-01** — Reported Q4 and full-year 2025 results: $94.2 billion in sales, up ~6%, with adjusted EPS of $10.79.
- **2025-01** — Outlined roughly $92 billion in 2025 sales guidance driven by Innovative Medicine and MedTech growth.
- **2025-01** — Announced intent to spin off the DePuy Synthes orthopaedics business over 18 to 24 months to focus on higher-growth segments.
- **2023-05** — Completed the separation of consumer-health business Kenvue (NYSE: KVUE).

## Links

- Website: https://www.jnj.com
- LinkedIn: https://www.linkedin.com/company/johnson-&-johnson
- Twitter/X: https://twitter.com/JNJCares
- YouTube: https://www.youtube.com/user/JNJhealth
- Instagram: https://www.instagram.com/jnj
- Facebook: https://www.facebook.com/jnj

---

Profile page: https://yespress.io/johnson-johnson
Published by YesPress — https://yespress.io
Last updated: 2026-08-12